Literature DB >> 15243052

Dissociation of serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus and treated with antiretroviral drugs.

Milena Furione1, Renato Maserati, Marta Gatti, Fausto Baldanti, Agostino Cividini, Raffaele Bruno, Giuseppe Gerna, Mario U Mondelli.   

Abstract

We examined hepatitis C virus (HCV) RNA levels in serum, peripheral blood mononuclear cells (PBMC), and the liver for 135 patients with chronic HCV infections, 44 of whom were human immunodeficiency virus (HIV) positive and treated with highly active antiretroviral therapy (group A), 66 of whom were HIV negative (group B), with abnormal serum alanine aminotransferase (ALT) values, and 25 of whom were HIV negative, with ALT values of </=1.5 times the normal value (group C). Patients had not been treated with interferon, with or without ribavirin, at the time of the study. A statistically significant correlation between HCV RNA levels in the liver and serum was reproducibly documented, whereas this was inconsistent for serum and PBMC. A comparative evaluation of HCV RNA levels in the liver and PBMC showed significantly lower values for group A than for groups B and C (P < 0.01 and P < 0.0001, respectively). In contrast, HCV RNA levels in serum were significantly higher for group A than for group B (P < 0.001). A dissociation between HCV RNA levels in serum and the liver was found for patients with HIV-HCV coinfections. Although the relative contribution of extrahepatic reservoirs, including lymphoid cells, to HCV RNA levels in serum is unclear, it may be speculated that a low intrahepatic HCV burden is caused by restored immunocompetence after successful antiretroviral therapy in coinfected patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15243052      PMCID: PMC446282          DOI: 10.1128/JCM.42.7.3012-3016.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.

Authors:  P Fialaire; C Payan; D Vitour; J M Chennebault; J Loison; E Pichard; F Lunel
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

2.  Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign?

Authors:  A Cividini; C Rebucci; E Silini; M U Mondelli
Journal:  Gastroenterology       Date:  2001-12       Impact factor: 22.682

3.  Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection.

Authors:  P Trimoulet; D Neau; B Le Bail; A Rullier; M Winnock; T Galperine; E Legrand; E Schvoerer; M Dupon; J M Ragnaud; P Bioulac-Sage; G Chêne; H Fleury; M E Lafon
Journal:  J Med Virol       Date:  2002-06       Impact factor: 2.327

4.  Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.

Authors:  Georg M Lauer; Tam N Nguyen; Cheryl L Day; Gregory K Robbins; Theresa Flynn; Katherine McGowan; Eric S Rosenberg; Michaela Lucas; Paul Klenerman; Raymond T Chung; Bruce D Walker
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection.

Authors:  Peter M Rosenberg; James J Farrell; Diane R Abraczinskas; Fiona M Graeme-Cook; Jules L Dienstag; Raymond T Chung
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

6.  Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy.

Authors:  Marina Núñez; Pilar Ríos; Luz Martín-Carbonero; Mayte Pérez-Olmeda; Juan González-Lahoz; Vincent Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2002-05-01       Impact factor: 3.731

Review 7.  Management of hepatitis C in HIV-infected persons.

Authors:  R Rodríguez-Rosado; M Pérez-Olmeda; J García-Samaniego; V Soriano
Journal:  Antiviral Res       Date:  2001-11       Impact factor: 5.970

8.  Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus.

Authors:  Curtis L Cooper; M A Parbhakar; Jonathan B Angel
Journal:  Clin Infect Dis       Date:  2002-03-28       Impact factor: 9.079

9.  Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.

Authors:  Raymond T Chung; Scott R Evans; Yijun Yang; Dickens Theodore; Hernan Valdez; Rebecca Clark; Cecilia Shikuma; Thomas Nevin; Kenneth E Sherman
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

10.  Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection.

Authors:  Vicky M-H Sung; Shigetaka Shimodaira; Alison L Doughty; Gaston R Picchio; Huong Can; T S Benedict Yen; Karen L Lindsay; Alexandra M Levine; Michael M C Lai
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  1 in total

1.  Cellular activation and intracellular HCV load in peripheral blood monocytes isolated from HCV monoinfected and HIV-HCV coinfected patients.

Authors:  Isabelle Dichamp; Wasim Abbas; Amit Kumar; Vincent Di Martino; Georges Herbein
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.